Načítá se...

Use of class I histone deacetylase inhibitor romidepsin in combination regimens

Histone deacetylase (HDAC) inhibitors are epigenetic-modifying agents that have shown promise as anticancer therapies. Several HDAC inhibitors have been approved by the US Food and Drug Administration (FDA) as single-agent therapies to treat T-cell lymphoma. The synergistic combination of HDAC inhib...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Leuk Lymphoma
Hlavní autoři: Petrich, Adam, Nabhan, Chadi
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2016
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4950458/
https://ncbi.nlm.nih.gov/pubmed/27118119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2016.1160082
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!